Amgen Inc. (AMGN) Stock Analysis
Range Bound setup
Healthcare · Drug Manufacturers - General
Sell if holding. Analyst target reached at $330.75 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 6.2): -1.5.
Amgen discovers, develops, and manufactures biologic medicines across oncology, cardiovascular, bone, inflammatory diseases, and neuroscience with $35.1B in product revenues in 2025. Revenue is primarily from U.S. sales (73%) distributed through three major wholesalers that... Read more
Sell if holding. Analyst target reached at $330.75 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 6.2): -1.5. Chart setup: RSI 46 mid-range, Bollinger mid-band. Score 5.6/10, moderate confidence.
Passes 6/10 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and news legal and news soft fda negative. Suitability: conservative.
Recent Developments — Amgen Inc.
Latest news
- Earnings To Watch: Amgen (AMGN) Reports Q1 Results Tomorrow - Yahoo Finance — Yahoo Finance neutral
- Earnings To Watch: Amgen (AMGN) Reports Q1 Results Tomorrow - StockStory — StockStory neutral
- The Bull Case For Amgen (AMGN) Could Change Following Strong Q4 Beat And Upbeat 2026 Guidance - simplywall.st — simplywall.st positive
- AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER - PR Newswire — PR Newswire neutral
- Amgen (NASDAQ:AMGN) Earns Neutral Rating from Cantor Fitzgerald - MarketBeat — MarketBeat neutral
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $330.75 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 6.2): -1.5. Chart setup: RSI 46 mid-range, Bollinger mid-band. Prior stop was $314.01. Score 5.6/10, moderate confidence.
Take-profit target: $341.10 (+3.1% upside). Prior stop was $314.01. Stop-loss: $314.01.
Analyst target reached - limited upside remaining; Leverage penalty (D/E 6.2): -1.5; Weak growth.
Amgen Inc. trades at a P/E of 22.6 (forward 13.8). TrendMatrix value score: 5.6/10. Verdict: Sell.
44 analysts cover AMGN with a consensus score of 3.5/5. Average price target: $352.
What does Amgen Inc. do?Amgen discovers, develops, and manufactures biologic medicines across oncology, cardiovascular, bone, inflammatory...
Amgen discovers, develops, and manufactures biologic medicines across oncology, cardiovascular, bone, inflammatory diseases, and neuroscience with $35.1B in product revenues in 2025. Revenue is primarily from U.S. sales (73%) distributed through three major wholesalers that collectively account for 77% of worldwide gross revenues.